安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits . . .
Here, we produced U3-1402, an anti-HER3 antibody-drug conjugate with a topoisomerase I inhibitor exatecan derivative (DXd), and systematically investigated its targeted drug delivery potential and antitumor activity in preclinical models
- AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a . . .
A HER3-targeting ADC with an improved therapeutic index in U3-1402–insensitive tumors, including low-HER3 expression lung cancer or colon cancer, will likely expand responding patient population and applicable tumor types to realize the full potential of HER3 as a tumor antigen broadly overexpressed in solid tumors
- Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor . . .
Patritumab deruxtecan (HER3-DXd) is an investigational HER3-targeted antibody-drug conjugate that is being evaluated as a novel treatment in HER3-expressing advanced breast cancer in the U31402-A-J101 study Adults with disease progression on previous therapies were eligible
- HER3-targeted therapeutic antibodies and antibody–drug conjugates in . . .
A novel HER3-targeting antibody-drug conjugate, U3-1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization
- An HER3-targeting antibody–drug conjugate incorporating a DNA . . .
U3-1402 is an anti-HER3 antibody–drug conjugate with a novel topoisomerase I inhibitor, DXd In the current study, we evaluated the anticancer efficacy of U3-1402 in EGFR-mutant
- AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate . . . - PubMed
AMT-562 has potential to be a superior HER3-targeting ADC with a higher therapeutic window that can overcome resistance to generate higher percentage and more durable responses in U3-1402-insensitive tumors
- Single agent activity of U3-1402, a HER3-targeting antibody-drug . . .
Background: U3-1402 is a human epidermal growth factor receptor 3 (HER3)-targeting antibody-drug conjugate (ADC) of high drug-to-antibody-ratio (DAR: 7 to 8) with a novel linker and topoisomerase I inhibitor payload HER3 is overexpressed in a variety of cancers, including breast, lung, colorectal, ovarian, prostate and urothelial cancer
- A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits . . .
Here, we engineered a novel HER3-targeting ADC, U3-1402, and demonstrated its HER3-specific and payload drug-derived antitumor activity in preclinical cancer models
|
|
|